Combination PEG-IFN α-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 529-532

  Ishikawa, Toru ^a   Higuchi, Kazuo ^a   Kubota, Tomoyuki ^a   Seki, Kei Ichi ^a   Honma, Terasu ^a   Yoshida, Toshiaki ^a   Kamimura, Tomoteru ^a  

^a Saiseikai Niigata Second Hospital   (Japan)

Author keywords

Hepatic functional reserve; Hepatocellular carcinoma; Peg IFN 2b ribavirin therapy; Secondary prevention

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SERUM ALBUMIN;

ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATECTOMY; HEPATITIS C; HUMANS; INTERFERON-ALPHA; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860573148     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10867     Document Type: Article

References (24)

1. Rossi S, Garbagnati F, Lencioni R, et al.: Percutaneous radio-frequency thermal ablation of non-resectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217:119-126. (Pubitemid 33097587)
2. Nagasue N, Uchida M, Makino Y, et al.: Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105:488-494.
3. Yamamoto J, Kosuge T, Takayama T, et al.: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83:1219-1922.
4. Yoshida H, Shiratori Y, Moriyama M, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of Hepatocarcinogenesis by Interferon Therapy Study Group. Ann Intern Med 1999; 131:174-181. (Pubitemid 29364999)
5. Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-524. (Pubitemid 30171890)
6. Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-524. (Pubitemid 30171890)
7. Ikeda K, Arase Y, Saitoh S, et al.: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228-232. (Pubitemid 30614654)
8. Kubo S, Nishiguchi S, Hirohashi K, et al.: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134:963-967. (Pubitemid 32466235)
9. Shiratori Y, Shiina S, Teratani T, et al.: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299-306. (Pubitemid 36205926)
10. Sakaguchi Y, Kudo M, Fukunaga T, et al.: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48:64-70. (Pubitemid 40529213)
11. Ishikawa T: Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008; 28:6140-6144.
12. Llovet JM, Burroghs, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
13. Sherlock S: Viruses and hepatocellular carcinoma. Gut 1994; 35:828-832.
14. Nakashima O, Kojiro M: Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001; 8:404-409. (Pubitemid 33725570)
15. Notsumata K, Shimizu M, Unoura M, et al.: Study of percutaneous ethanol injection therapy (PEIT) under ultrasonography in hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi 1988; 85:2666-2672. (In Japanese with English abstract). (Pubitemid 19042359)
16. Suou T, Mitsuda A, Koda M, et al.: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20:301-311. (Pubitemid 32573892)
17. Ishikawa T, Ichida T, Yamagiwa S, et al.: High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16:1274-1281. (Pubitemid 34088276)
18. Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
19. Bruix J, Sherman M: Diagnosis of Small HCC. Gastroenterology 2005; 129:1364.
20. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229:322-330. (Pubitemid 30191766)
21. Dienstag JL, McHutchison JG: American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-264. (Pubitemid 43049856)
22. Strader DB, Wright T, Thomas DL, Seeff LB: American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
23. Fried MW, Shiftman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
24. Katano Y, Kumada T, Nakano I, et al.: Comparison of biochemical safety between PEG-IFN α-2a and PEG-IFN α-2b. Hepatogastroenterol 2009; 56:485-491.